Predictive Oncology Inc. (NASDAQ:POAI) has introduced a cutting-edge 3D cell culture model to revolutionize cancer drug discovery and facilitate future drug development efforts. The company’s organ-specific in vitro models are designed to replicate the human tissue’s physiological environment more accurately than traditional 2D assays.
These advanced 3D cell cultures closely mimic human tissue architecture and provide a more representative method for predicting clinical outcomes and optimizing drug candidate selection for subsequent clinical development. By incorporating these complex 3D cell applications into drug discovery processes, Predictive Oncology aims to accelerate time-to-market, reduce drug development costs, minimize the need for animal testing, and streamline clinical trials.
Raymond Vennare, Predictive Oncology’s CEO, emphasized the significance of using 3D cell models in drug discovery and development to enhance the efficiency and accuracy of predicting drug response. The company’s customizable organ- and disease-specific models preserve critical interactions between tumors and their cellular surroundings, offering a versatile platform compatible with various cell types and drug classes.
Dr. Arlette Uihlein, SVP of Translational Medicine at Predictive Oncology, highlighted the groundbreaking work on 3D organoids and spheroids using AI and machine learning technologies to predict drug response for oncology modeling and other applications. Recent studies presented at the Society for Laboratory Automation and Screening showcased the importance of leveraging 3D tumor models like r-Breast and r-Pancreas for enhanced drug discovery outcomes.
The 3D cell culture market is poised for substantial growth, with projections indicating a surge from $1.4 billion in 2022 to nearly $5.3 billion annually by 2032, driven by applications in pharmaceuticals, regenerative medicine, cancer research, and toxicology. These advanced cell cultures play a pivotal role in predicting drug efficacy, toxicity, and pharmacokinetics more accurately than traditional methods, ultimately reducing drug candidate attrition rates in later clinical trial stages.
Predictive Oncology leverages its AI platform, PEDAL, which can predict drug response with 92% accuracy in tumor samples, to offer comprehensive AI-based drug discovery solutions to its academic and industry partners. With a vast biobank of over 150,000 assay-capable human tumor samples and state-of-the-art CLIA lab and GMP facilities, the company is at the forefront of utilizing AI-driven technology to expedite early drug discovery and development for the benefit of cancer patients worldwide.
Investor Relations Contact:
Tim McCarthy
LifeSci Advisors, LLC
tim@lifesciadvisors.com
Source:
Precedence Research
https://www.biospace.com/article/releases/3d-cell-culture-market-size-to-attain-around-usd-5-29-bn-by-2032
Predictive Oncology’s innovative 3D cell culture model represents a significant advancement in cancer therapeutic drug discovery, offering a highly accurate and efficient approach to predicting drug response and optimizing clinical outcomes.
